董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roderick Wong | 男 | Chairman of the Board | 47 | 未披露 | 未持股 | 2025-09-30 |
| Gaurav D. Shah | 男 | Director and Chief Executive Officer | 50 | 未披露 | 未持股 | 2025-09-30 |
| Piratip Pratuwan | -- | Director | -- | 未披露 | 未持股 | 2025-09-30 |
| Mikael Dolsten | -- | Director | -- | 未披露 | 未持股 | 2025-09-30 |
| Fady Ibraham Malik | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-30 |
| Elisabeth Bjork | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-30 |
| Peter Fong | -- | Director | -- | 未披露 | 未持股 | 2025-09-30 |
| David P. Southwell | 男 | Independent Director | 64 | 128.11万美元 | 未持股 | 2025-09-30 |
| Carsten Boess | 男 | Independent Director | 58 | 13.23万美元 | 未持股 | 2025-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gaurav D. Shah | 男 | Director and Chief Executive Officer | 50 | 未披露 | 未持股 | 2025-09-30 |
| Jonathan Schwartz | 男 | Chief Medical Officer and Chief Gene Therapy Officer | 61 | 未披露 | 未持股 | 2025-09-30 |
| John Militello | 男 | Vice President, Finance, Treasurer and Principal Accounting Officer | 51 | 未披露 | 未持股 | 2025-09-30 |
| Christopher Stevens | 男 | Chief Operating Officer | 45 | 未披露 | 未持股 | 2025-09-30 |
| Sarbani Chaudhuri | -- | Chief Commercial Officer and Chief Medical Affairs Officer | -- | 未披露 | 未持股 | 2025-09-30 |
| Martin Wilson | -- | Interim Principal Financial Officer,Chief Corporate Officer, Senior Vice President and General Counsel | -- | 未披露 | 未持股 | 2025-09-30 |
董事简历
中英对照 | 中文 | 英文- Roderick Wong
-
Roderick Wong自2019年8月起担任董事。Wong博士自2010年以来担任RTW Investments，LP的管理合伙人兼首席投资官。黄博士此前于2018年12月至2019年12月担任Health Sciences Acquisition Corporation的总裁，首席执行官兼董事长。他自2015年7月起担任Rocket Pharmaceuticals，Inc.董事会主席，自2020年6月起担任AvidityBiosciences，Inc.董事会成员。Wong博士拥有杜克大学（Duke University）经济学学士学位，宾夕法尼亚大学医学院（University of Pennsylvania Medical School）医学博士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
Roderick Wong has served as Chairman of Rocket Pharmaceuticals, Inc. Board since January 2018 when he joined the Board in connection with the Reverse Merger. Dr. Wong served as the Chairman of the Board for Private Rocket from July 2015 until January 2018. Dr. Wong has over 15 years of healthcare investment experience. Since 2010 he has served as Managing Partner and Chief Investment Officer of RTW Investments, LP "RTW", a healthcare-centered investment firm. Prior to RTW, Dr. Wong was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. Prior to joining Davidson Kempner, Dr. Wong held various healthcare investment and healthcare research roles at SAC Capital Company and Cowen & Company. Dr. Wong served on the Board of Directors of Penwest Pharmaceuticals in 2010. He received an MD from the University of Pennsylvania Medical School, received an MBA from Harvard Business School, and graduated with a BS in Economics from Duke University. - Roderick Wong自2019年8月起担任董事。Wong博士自2010年以来担任RTW Investments，LP的管理合伙人兼首席投资官。黄博士此前于2018年12月至2019年12月担任Health Sciences Acquisition Corporation的总裁，首席执行官兼董事长。他自2015年7月起担任Rocket Pharmaceuticals，Inc.董事会主席，自2020年6月起担任AvidityBiosciences，Inc.董事会成员。Wong博士拥有杜克大学（Duke University）经济学学士学位，宾夕法尼亚大学医学院（University of Pennsylvania Medical School）医学博士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
- Roderick Wong has served as Chairman of Rocket Pharmaceuticals, Inc. Board since January 2018 when he joined the Board in connection with the Reverse Merger. Dr. Wong served as the Chairman of the Board for Private Rocket from July 2015 until January 2018. Dr. Wong has over 15 years of healthcare investment experience. Since 2010 he has served as Managing Partner and Chief Investment Officer of RTW Investments, LP "RTW", a healthcare-centered investment firm. Prior to RTW, Dr. Wong was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. Prior to joining Davidson Kempner, Dr. Wong held various healthcare investment and healthcare research roles at SAC Capital Company and Cowen & Company. Dr. Wong served on the Board of Directors of Penwest Pharmaceuticals in 2010. He received an MD from the University of Pennsylvania Medical School, received an MBA from Harvard Business School, and graduated with a BS in Economics from Duke University.
- Gaurav D. Shah
-
Gaurav D.Shah自2020年12月起担任我们的董事会成员。Shah博士自2015年10月起担任Rocket Pharmaceuticals NASDAQ:RCKT的联合创始人，总裁兼首席执行官，自2020年6月起担任董事会成员。在此之前，Shah博士于2011年1月至2015年9月在Novartis AG（纽约证券交易所代码:NVS）担任多个领导职位，包括CAR-T-19全球临床项目负责人CTL-019和生物仿制药，以及Afinitor全球临床负责人。任职Novartis公司之前，Shah博士曾于2008年7月至2010年12月担任礼来公司（纽约证券交易所代码:LLY）的医疗董事，在那里他负责多个项目的临床开发，包括Olaratumab。在他的行业任期内，他参与了几个药物开发计划，导致成功的监管批准，如CTL-019在儿科ALL，在美国批准的第一个细胞和基因疗法，以及各种成功的商业启动。在此之前，Shah博士是哥伦比亚大学（Columbia University）的医学/肿瘤学助理教授。Shah博士持有Harvard College（优等成绩，Phi Beta Kappa）的行为神经科学学士学位，以及Columbia University的医学博士学位。Shah博士还在Brigham and Women&8217；s Hospital完成了内科住院医师资格，并在Memorial-Sloan Kettering完成了血液学/肿瘤学奖学金培训。
Gaurav D. Shah has served as a member of board of directors since December 2020. Dr. Shah has served as the co-founder, President, and Chief Executive Officer since October 2015 and a member of the board of directors since June 2020 of Rocket Pharmaceuticals Nasdaq: RCKT. Prior to this role, from January 2011 to September 2015 Dr. Shah held various leadership positions at Novartis AG (NYSE: NVS), including Global Program Head for CAR-T-19 Global Clinical Program Head for CTL-019 and Biosimilars, and Global Clinical Leader for Afinitor. Prior to Novartis, Dr. Shah was a Medical Director at Eli Lilly and Company (NYSE: LLY) from July 2008 to December 2010 where he oversaw clinical development of numerous programs, including olaratumab. During his industry tenure, he has participated in several drug development programs resulting in successful regulatory approvals, such as CTL-019 in pediatric ALL, the first cell and gene therapy approved in the U.S., as well as various successful commercial launches. Prior to that, Dr. Shah was an Assistant Professor of Medicine/Oncology at Columbia University. Dr. Shah holds his BSc in behavioral neuroscience from Harvard College (summa cum laude, Phi Beta Kappa) and a MD from Columbia University. Dr. Shah also completed his internal medicine residency at Brigham and Women's Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering. - Gaurav D.Shah自2020年12月起担任我们的董事会成员。Shah博士自2015年10月起担任Rocket Pharmaceuticals NASDAQ:RCKT的联合创始人，总裁兼首席执行官，自2020年6月起担任董事会成员。在此之前，Shah博士于2011年1月至2015年9月在Novartis AG（纽约证券交易所代码:NVS）担任多个领导职位，包括CAR-T-19全球临床项目负责人CTL-019和生物仿制药，以及Afinitor全球临床负责人。任职Novartis公司之前，Shah博士曾于2008年7月至2010年12月担任礼来公司（纽约证券交易所代码:LLY）的医疗董事，在那里他负责多个项目的临床开发，包括Olaratumab。在他的行业任期内，他参与了几个药物开发计划，导致成功的监管批准，如CTL-019在儿科ALL，在美国批准的第一个细胞和基因疗法，以及各种成功的商业启动。在此之前，Shah博士是哥伦比亚大学（Columbia University）的医学/肿瘤学助理教授。Shah博士持有Harvard College（优等成绩，Phi Beta Kappa）的行为神经科学学士学位，以及Columbia University的医学博士学位。Shah博士还在Brigham and Women&8217；s Hospital完成了内科住院医师资格，并在Memorial-Sloan Kettering完成了血液学/肿瘤学奖学金培训。
- Gaurav D. Shah has served as a member of board of directors since December 2020. Dr. Shah has served as the co-founder, President, and Chief Executive Officer since October 2015 and a member of the board of directors since June 2020 of Rocket Pharmaceuticals Nasdaq: RCKT. Prior to this role, from January 2011 to September 2015 Dr. Shah held various leadership positions at Novartis AG (NYSE: NVS), including Global Program Head for CAR-T-19 Global Clinical Program Head for CTL-019 and Biosimilars, and Global Clinical Leader for Afinitor. Prior to Novartis, Dr. Shah was a Medical Director at Eli Lilly and Company (NYSE: LLY) from July 2008 to December 2010 where he oversaw clinical development of numerous programs, including olaratumab. During his industry tenure, he has participated in several drug development programs resulting in successful regulatory approvals, such as CTL-019 in pediatric ALL, the first cell and gene therapy approved in the U.S., as well as various successful commercial launches. Prior to that, Dr. Shah was an Assistant Professor of Medicine/Oncology at Columbia University. Dr. Shah holds his BSc in behavioral neuroscience from Harvard College (summa cum laude, Phi Beta Kappa) and a MD from Columbia University. Dr. Shah also completed his internal medicine residency at Brigham and Women's Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering.
- Piratip Pratuwan
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mikael Dolsten
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Fady Ibraham Malik
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Elisabeth Bjork
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Peter Fong
-
Peter Fong，目前担任RTW Investments LP总裁，加入董事会。
Peter Fong,currently serves as President of RTW Investments LP, to the Board. - Peter Fong，目前担任RTW Investments LP总裁，加入董事会。
- Peter Fong,currently serves as President of RTW Investments LP, to the Board.
- David P. Southwell
-
David P. Southwell 自 2014 年 8 月起担任 Rocket Pharmaceuticals, Inc. 董事之一。他于 2014 年 7 月至 2018 年 1 月担任 Rocket Pharmaceuticals, Inc. 总裁兼首席执行官。从 2010 年 3 月至 2012 年 10 月，Southwell 先生担任 Human Genome Sciences, Inc. 或 Human Genome Sciences 的执行副总裁兼首席财务官，Human Genome Sciences, Inc.由 GlaxoSmithKline plc 拥有。 在加入 Human Genome Sciences 之前，Southwell 先生于 1994 年 7 月至 2008 年 7 月担任 Sepracor Inc. 的执行副总裁兼首席财务官。Southwell 先生自 12 月起还担任 PTC Therapeutics Inc. 的董事会成员 2005 年和 Spero Therapeutics, Inc. 自 2018 年 2 月起。Southwell 先生获得了学士学位。 莱斯大学和达特茅斯学院工商管理硕士。
David P. Southwell has served as one of Rocket Pharmaceuticals, Inc. directors since August 2014. He served as Rocket Pharmaceuticals, Inc. President and Chief Executive Officer from July 2014 to January 2018. From March 2010 to October 2012 Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc., or Human Genome Sciences, which is owned by GlaxoSmithKline plc. Prior to his time at Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor Inc. from July 1994 to July 2008. Mr. Southwell has also served on the Board of Directors of PTC Therapeutics Inc. since December 2005 and Spero Therapeutics, Inc. since February 2018. Mr. Southwell received a B.A. from Rice University and an M.B.A. from Dartmouth College. - David P. Southwell 自 2014 年 8 月起担任 Rocket Pharmaceuticals, Inc. 董事之一。他于 2014 年 7 月至 2018 年 1 月担任 Rocket Pharmaceuticals, Inc. 总裁兼首席执行官。从 2010 年 3 月至 2012 年 10 月，Southwell 先生担任 Human Genome Sciences, Inc. 或 Human Genome Sciences 的执行副总裁兼首席财务官，Human Genome Sciences, Inc.由 GlaxoSmithKline plc 拥有。 在加入 Human Genome Sciences 之前，Southwell 先生于 1994 年 7 月至 2008 年 7 月担任 Sepracor Inc. 的执行副总裁兼首席财务官。Southwell 先生自 12 月起还担任 PTC Therapeutics Inc. 的董事会成员 2005 年和 Spero Therapeutics, Inc. 自 2018 年 2 月起。Southwell 先生获得了学士学位。 莱斯大学和达特茅斯学院工商管理硕士。
- David P. Southwell has served as one of Rocket Pharmaceuticals, Inc. directors since August 2014. He served as Rocket Pharmaceuticals, Inc. President and Chief Executive Officer from July 2014 to January 2018. From March 2010 to October 2012 Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc., or Human Genome Sciences, which is owned by GlaxoSmithKline plc. Prior to his time at Human Genome Sciences, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Sepracor Inc. from July 1994 to July 2008. Mr. Southwell has also served on the Board of Directors of PTC Therapeutics Inc. since December 2005 and Spero Therapeutics, Inc. since February 2018. Mr. Southwell received a B.A. from Rice University and an M.B.A. from Dartmouth College.
- Carsten Boess
-
Carsten Boess 自 2016 年 1 月起担任 Rocket Pharmaceuticals, Inc. 的董事之一。他目前是私营生物技术公司 Kiniksa Pharmaceuticals 的企业事务执行副总裁。他曾在 2011 年担任 Synageva Biopharma Corporation 的高级副总裁兼首席财务官，直到Synageva Biopharma Corporation 于 2015 年被 Alexion Pharmaceuticals 收购。在加入 Synageva 之前，Boess 先生曾担任多个职务，对 Insulet Corporation 的责任越来越大，包括首席财务官2006 年至 2009 年担任财务官，2009 年至 2011 年担任国际运营副总裁。在此之前，Boess 先生于 2005 年至 2006 年担任雪兰诺公司的财务执行副总裁。此外，他还是日内瓦的成员在雪兰诺期间，总部位于全球执行财务管理团队。 Boess 先生还曾担任 Alexion Pharmaceuticals 的首席财务官，以及北美 Novozymes 和法国、瑞士和中国的 Novo Nordisk 的财务主管。 Boess 先生获得丹麦欧登塞大学会计与金融专业的经济学和金融学学士和硕士学位。
Carsten Boess has served as one of Rocket Pharmaceuticals, Inc. directors since January 2016. He is currently the Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, a privately held biotechnology company. He previously served as Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation from 2011 until the company's acquisition by Alexion Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served in multiple roles with increasing responsibility for Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance for Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva based World Wide Executive Finance Management Team while at Serono. Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals and was a finance executive at Novozymes of North America and Novo Nordisk in France, Switzerland and China. Mr. Boess received a Bachelor's degree and Master's degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark. - Carsten Boess 自 2016 年 1 月起担任 Rocket Pharmaceuticals, Inc. 的董事之一。他目前是私营生物技术公司 Kiniksa Pharmaceuticals 的企业事务执行副总裁。他曾在 2011 年担任 Synageva Biopharma Corporation 的高级副总裁兼首席财务官，直到Synageva Biopharma Corporation 于 2015 年被 Alexion Pharmaceuticals 收购。在加入 Synageva 之前，Boess 先生曾担任多个职务，对 Insulet Corporation 的责任越来越大，包括首席财务官2006 年至 2009 年担任财务官，2009 年至 2011 年担任国际运营副总裁。在此之前，Boess 先生于 2005 年至 2006 年担任雪兰诺公司的财务执行副总裁。此外，他还是日内瓦的成员在雪兰诺期间，总部位于全球执行财务管理团队。 Boess 先生还曾担任 Alexion Pharmaceuticals 的首席财务官，以及北美 Novozymes 和法国、瑞士和中国的 Novo Nordisk 的财务主管。 Boess 先生获得丹麦欧登塞大学会计与金融专业的经济学和金融学学士和硕士学位。
- Carsten Boess has served as one of Rocket Pharmaceuticals, Inc. directors since January 2016. He is currently the Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, a privately held biotechnology company. He previously served as Senior Vice President and Chief Financial Officer at Synageva Biopharma Corporation from 2011 until the company's acquisition by Alexion Pharmaceuticals in 2015. Prior to his role at Synageva, Mr. Boess served in multiple roles with increasing responsibility for Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance for Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva based World Wide Executive Finance Management Team while at Serono. Mr. Boess was also Chief Financial Officer at Alexion Pharmaceuticals and was a finance executive at Novozymes of North America and Novo Nordisk in France, Switzerland and China. Mr. Boess received a Bachelor's degree and Master's degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark.
高管简历
中英对照 | 中文 | 英文- Gaurav D. Shah
Gaurav D.Shah自2020年12月起担任我们的董事会成员。Shah博士自2015年10月起担任Rocket Pharmaceuticals NASDAQ:RCKT的联合创始人，总裁兼首席执行官，自2020年6月起担任董事会成员。在此之前，Shah博士于2011年1月至2015年9月在Novartis AG（纽约证券交易所代码:NVS）担任多个领导职位，包括CAR-T-19全球临床项目负责人CTL-019和生物仿制药，以及Afinitor全球临床负责人。任职Novartis公司之前，Shah博士曾于2008年7月至2010年12月担任礼来公司（纽约证券交易所代码:LLY）的医疗董事，在那里他负责多个项目的临床开发，包括Olaratumab。在他的行业任期内，他参与了几个药物开发计划，导致成功的监管批准，如CTL-019在儿科ALL，在美国批准的第一个细胞和基因疗法，以及各种成功的商业启动。在此之前，Shah博士是哥伦比亚大学（Columbia University）的医学/肿瘤学助理教授。Shah博士持有Harvard College（优等成绩，Phi Beta Kappa）的行为神经科学学士学位，以及Columbia University的医学博士学位。Shah博士还在Brigham and Women&8217；s Hospital完成了内科住院医师资格，并在Memorial-Sloan Kettering完成了血液学/肿瘤学奖学金培训。
Gaurav D. Shah has served as a member of board of directors since December 2020. Dr. Shah has served as the co-founder, President, and Chief Executive Officer since October 2015 and a member of the board of directors since June 2020 of Rocket Pharmaceuticals Nasdaq: RCKT. Prior to this role, from January 2011 to September 2015 Dr. Shah held various leadership positions at Novartis AG (NYSE: NVS), including Global Program Head for CAR-T-19 Global Clinical Program Head for CTL-019 and Biosimilars, and Global Clinical Leader for Afinitor. Prior to Novartis, Dr. Shah was a Medical Director at Eli Lilly and Company (NYSE: LLY) from July 2008 to December 2010 where he oversaw clinical development of numerous programs, including olaratumab. During his industry tenure, he has participated in several drug development programs resulting in successful regulatory approvals, such as CTL-019 in pediatric ALL, the first cell and gene therapy approved in the U.S., as well as various successful commercial launches. Prior to that, Dr. Shah was an Assistant Professor of Medicine/Oncology at Columbia University. Dr. Shah holds his BSc in behavioral neuroscience from Harvard College (summa cum laude, Phi Beta Kappa) and a MD from Columbia University. Dr. Shah also completed his internal medicine residency at Brigham and Women's Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering.- Gaurav D.Shah自2020年12月起担任我们的董事会成员。Shah博士自2015年10月起担任Rocket Pharmaceuticals NASDAQ:RCKT的联合创始人，总裁兼首席执行官，自2020年6月起担任董事会成员。在此之前，Shah博士于2011年1月至2015年9月在Novartis AG（纽约证券交易所代码:NVS）担任多个领导职位，包括CAR-T-19全球临床项目负责人CTL-019和生物仿制药，以及Afinitor全球临床负责人。任职Novartis公司之前，Shah博士曾于2008年7月至2010年12月担任礼来公司（纽约证券交易所代码:LLY）的医疗董事，在那里他负责多个项目的临床开发，包括Olaratumab。在他的行业任期内，他参与了几个药物开发计划，导致成功的监管批准，如CTL-019在儿科ALL，在美国批准的第一个细胞和基因疗法，以及各种成功的商业启动。在此之前，Shah博士是哥伦比亚大学（Columbia University）的医学/肿瘤学助理教授。Shah博士持有Harvard College（优等成绩，Phi Beta Kappa）的行为神经科学学士学位，以及Columbia University的医学博士学位。Shah博士还在Brigham and Women&8217；s Hospital完成了内科住院医师资格，并在Memorial-Sloan Kettering完成了血液学/肿瘤学奖学金培训。
- Gaurav D. Shah has served as a member of board of directors since December 2020. Dr. Shah has served as the co-founder, President, and Chief Executive Officer since October 2015 and a member of the board of directors since June 2020 of Rocket Pharmaceuticals Nasdaq: RCKT. Prior to this role, from January 2011 to September 2015 Dr. Shah held various leadership positions at Novartis AG (NYSE: NVS), including Global Program Head for CAR-T-19 Global Clinical Program Head for CTL-019 and Biosimilars, and Global Clinical Leader for Afinitor. Prior to Novartis, Dr. Shah was a Medical Director at Eli Lilly and Company (NYSE: LLY) from July 2008 to December 2010 where he oversaw clinical development of numerous programs, including olaratumab. During his industry tenure, he has participated in several drug development programs resulting in successful regulatory approvals, such as CTL-019 in pediatric ALL, the first cell and gene therapy approved in the U.S., as well as various successful commercial launches. Prior to that, Dr. Shah was an Assistant Professor of Medicine/Oncology at Columbia University. Dr. Shah holds his BSc in behavioral neuroscience from Harvard College (summa cum laude, Phi Beta Kappa) and a MD from Columbia University. Dr. Shah also completed his internal medicine residency at Brigham and Women's Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering.
- Jonathan Schwartz
Jonathan Schwartz于2018年1月加入Rocket制药公司，担任首席医疗官，处理反向合并事宜。Schwartz博士于2016年1月加入Private Rocket，担任首席医疗官和临床开发主管。Schwartz博士负责领导Rocket制药公司的医疗和项目开发。Schwartz博士拥有超过20年的临床实践和药物开发经验。在加入Private Rocket之前，Schwartz博士是Stemline医疗临床开发副总裁，负责监督抗癌、疫苗和小分子平台的开发工作，他自2014年起担任该职位。在加入Stemline之前，他在礼来公司工作了七年，担任过多个领导职位，包括临床科学副总裁，在那里他领导了包括ramucirumab在内的众多药物项目的开发团队。此前，Schwartz博士是纽约西奈山医学中心的医学副教授，专门从事肝胆恶性肿瘤的治疗和转化研究，并担任血液学-肿瘤学奖学金培训计划的主任。他拥有布朗大学的美国文明学士学位和圣路易斯华盛顿大学的医学博士学位。他在西奈山医院和纽约长老会医院完成了研究生内科和血液肿瘤学培训。
Jonathan Schwartz joined Rocket Pharmaceuticals, Inc. as Chief Medical Officer in January 2018 in connection with the Reverse Merger. Dr. Schwartz joined Private Rocket in January 2016 and served as Chief Medical Officer and Head of Clinical Development. Dr. Schwartz is responsible for leading Rocket Pharmaceuticals, Inc. medical and program development. Dr. Schwartz has over 20 years of combined clinical practice and drug development experience. Prior to Private Rocket, Dr. Schwartz was Vice-President of Clinical Development at Stemline Therapeutics, where he oversaw development efforts for anticancer, vaccine and small-molecule platforms, a position he held since 2014. Prior to Stemline, he spent seven years at Eli Lilly and Company in several leadership positions, including Vice-President of Clinical Science, where he led development teams for numerous drug programs including ramucirumab. Previously, Dr. Schwartz was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies and also served as Director for the Hematology-Oncology Fellowship training program. He has a BA in American Civilization from Brown University and an MD from Washington University St. Louis. He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.- Jonathan Schwartz于2018年1月加入Rocket制药公司，担任首席医疗官，处理反向合并事宜。Schwartz博士于2016年1月加入Private Rocket，担任首席医疗官和临床开发主管。Schwartz博士负责领导Rocket制药公司的医疗和项目开发。Schwartz博士拥有超过20年的临床实践和药物开发经验。在加入Private Rocket之前，Schwartz博士是Stemline医疗临床开发副总裁，负责监督抗癌、疫苗和小分子平台的开发工作，他自2014年起担任该职位。在加入Stemline之前，他在礼来公司工作了七年，担任过多个领导职位，包括临床科学副总裁，在那里他领导了包括ramucirumab在内的众多药物项目的开发团队。此前，Schwartz博士是纽约西奈山医学中心的医学副教授，专门从事肝胆恶性肿瘤的治疗和转化研究，并担任血液学-肿瘤学奖学金培训计划的主任。他拥有布朗大学的美国文明学士学位和圣路易斯华盛顿大学的医学博士学位。他在西奈山医院和纽约长老会医院完成了研究生内科和血液肿瘤学培训。
- Jonathan Schwartz joined Rocket Pharmaceuticals, Inc. as Chief Medical Officer in January 2018 in connection with the Reverse Merger. Dr. Schwartz joined Private Rocket in January 2016 and served as Chief Medical Officer and Head of Clinical Development. Dr. Schwartz is responsible for leading Rocket Pharmaceuticals, Inc. medical and program development. Dr. Schwartz has over 20 years of combined clinical practice and drug development experience. Prior to Private Rocket, Dr. Schwartz was Vice-President of Clinical Development at Stemline Therapeutics, where he oversaw development efforts for anticancer, vaccine and small-molecule platforms, a position he held since 2014. Prior to Stemline, he spent seven years at Eli Lilly and Company in several leadership positions, including Vice-President of Clinical Science, where he led development teams for numerous drug programs including ramucirumab. Previously, Dr. Schwartz was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies and also served as Director for the Hematology-Oncology Fellowship training program. He has a BA in American Civilization from Brown University and an MD from Washington University St. Louis. He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.
- John Militello
John Militello于2018年1月加入Rocket制药公司，担任财务总监。2015年4月至2017年11月，Militello先生在上市生物技术公司副总裁公司工作，最近担任财务首席财务官、财务总监和Immune制药。在此之前，Militello先生是位于圣地亚哥的生物技术公司Retrophin, Inc.的助理财务总监，以及上市人力资源公司Volt Information Sciences, Inc.的外部报告与合规经理。在加入Volt Information Sciences, Inc.之前，Militello先生是BDO USA，LLP的高级经理，为跨国SEC注册人提供服务。Militello先生是一名注册会计师，并在圣约瑟夫学院获得会计学理学学士学位。
John Militello joined Rocket Pharmaceuticals, Inc. as Controller in January 2018. From April 2015 to November 2017 Mr. Militello worked at Immune Pharmaceuticals, Inc., a publicly traded biotechnology company, where he most recently served as Vice President of Finance principal financial officer, Controller and Chief Accounting Officer. Prior to that, Mr. Militello was an Assistant Controller with Retrophin, Inc., a San Diego based biotech company, and the Manager, External Reporting & Compliance at Volt Information Sciences, Inc., a publicly traded staffing company. Prior to Volt Information Sciences, Inc., Mr. Militello was a Senior Manager with BDO USA, LLP serving multi-national SEC registrants. Mr. Militello is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting from St. Joseph's College.- John Militello于2018年1月加入Rocket制药公司，担任财务总监。2015年4月至2017年11月，Militello先生在上市生物技术公司副总裁公司工作，最近担任财务首席财务官、财务总监和Immune制药。在此之前，Militello先生是位于圣地亚哥的生物技术公司Retrophin, Inc.的助理财务总监，以及上市人力资源公司Volt Information Sciences, Inc.的外部报告与合规经理。在加入Volt Information Sciences, Inc.之前，Militello先生是BDO USA，LLP的高级经理，为跨国SEC注册人提供服务。Militello先生是一名注册会计师，并在圣约瑟夫学院获得会计学理学学士学位。
- John Militello joined Rocket Pharmaceuticals, Inc. as Controller in January 2018. From April 2015 to November 2017 Mr. Militello worked at Immune Pharmaceuticals, Inc., a publicly traded biotechnology company, where he most recently served as Vice President of Finance principal financial officer, Controller and Chief Accounting Officer. Prior to that, Mr. Militello was an Assistant Controller with Retrophin, Inc., a San Diego based biotech company, and the Manager, External Reporting & Compliance at Volt Information Sciences, Inc., a publicly traded staffing company. Prior to Volt Information Sciences, Inc., Mr. Militello was a Senior Manager with BDO USA, LLP serving multi-national SEC registrants. Mr. Militello is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting from St. Joseph's College.
- Christopher Stevens
Christopher Stevens，最近于2022年10月至2025年7月在私营基因治疗公司星火治疗担任执行副总裁兼首席患者供应官，在那里他成功地领导了跨越制造、供应链、质量、合规、工程、EHS和设施的团队，在向全球患者提供基因疗法方面发挥了关键作用。在Spark任职期间，他还在2017年2月至2020年4月期间担任制造主管，通过批准并推出Luxturna，这是美国和欧盟批准的首个用于遗传病的基因疗法。史蒂文斯先生后来于2020年4月至2022年5月担任血友病A项目的资产总经理，随后于2022年5月至2022年10月担任产品战略主管，负责监督Spark整个投资组合的项目开发。在加入Spark之前，Stevens先生于2013年1月至2017年2月在全球生物制药公司葛兰素史克工作，在那里他领导的团队专注于战略、运营和规划，以及包括工艺转移和细胞银行在内的GMP临床制造业务。在其职业生涯的早期，他于2001年6月至2013年1月在全球生物制药公司百时美施贵宝担任越来越重要的职务，在马萨诸塞州、印第安纳州和波多黎各从事工艺工程、制造和供应链方面的工作。史蒂文斯先生目前在宾夕法尼亚州切斯特县的非营利家庭悲伤中心A Haven担任董事会主席。他在南印第安纳大学获得工业管理硕士学位，在普渡大学获得化学工程学士学位。
Christopher Stevens,most recently served as the Executive Vice President and Chief Patient Supply Officer from October 2022 through July 2025 at Spark Therapeutics, a private gene therapy company, where he successfully led teams across manufacturing, supply chain, quality, compliance, engineering, EHS, and facilities, playing a key role in delivering gene therapies to patients globally. During his tenure at Spark, he was also Head of Manufacturing from February 2017 through April 2020, through the approval and launch of Luxturna, the first gene therapy approved for a genetic disease in the U.S. and EU. Mr. Stevens later served as Asset General Manager, from April 2020 through May 2022, for the Hemophilia A program and subsequently Head of Product Strategy, from May 2022 through October 2022, overseeing program development for Spark's entire portfolio. Prior to Spark, Mr. Stevens was at GlaxoSmithKline, a global biopharma company, from January 2013 through February 2017, where he led teams focused on strategy, operations, and planning, as well as GMP clinical manufacturing operations including process transfer and cell banking. Earlier in his career he held roles of increasing responsibility at Bristol-Myers Squibb, a global biopharma company, from June 2001 through January 2013, in process engineering, manufacturing and supply chain in Massachusetts, Indiana and Puerto Rico. Mr. Stevens currently serves as President of the Board at A Haven – a non-profit family grief center in Chester County, Pennsylvania. He received his M.S. in Industrial Management from the University of Southern Indiana and a B.S. in Chemical Engineering from Purdue University.- Christopher Stevens，最近于2022年10月至2025年7月在私营基因治疗公司星火治疗担任执行副总裁兼首席患者供应官，在那里他成功地领导了跨越制造、供应链、质量、合规、工程、EHS和设施的团队，在向全球患者提供基因疗法方面发挥了关键作用。在Spark任职期间，他还在2017年2月至2020年4月期间担任制造主管，通过批准并推出Luxturna，这是美国和欧盟批准的首个用于遗传病的基因疗法。史蒂文斯先生后来于2020年4月至2022年5月担任血友病A项目的资产总经理，随后于2022年5月至2022年10月担任产品战略主管，负责监督Spark整个投资组合的项目开发。在加入Spark之前，Stevens先生于2013年1月至2017年2月在全球生物制药公司葛兰素史克工作，在那里他领导的团队专注于战略、运营和规划，以及包括工艺转移和细胞银行在内的GMP临床制造业务。在其职业生涯的早期，他于2001年6月至2013年1月在全球生物制药公司百时美施贵宝担任越来越重要的职务，在马萨诸塞州、印第安纳州和波多黎各从事工艺工程、制造和供应链方面的工作。史蒂文斯先生目前在宾夕法尼亚州切斯特县的非营利家庭悲伤中心A Haven担任董事会主席。他在南印第安纳大学获得工业管理硕士学位，在普渡大学获得化学工程学士学位。
- Christopher Stevens,most recently served as the Executive Vice President and Chief Patient Supply Officer from October 2022 through July 2025 at Spark Therapeutics, a private gene therapy company, where he successfully led teams across manufacturing, supply chain, quality, compliance, engineering, EHS, and facilities, playing a key role in delivering gene therapies to patients globally. During his tenure at Spark, he was also Head of Manufacturing from February 2017 through April 2020, through the approval and launch of Luxturna, the first gene therapy approved for a genetic disease in the U.S. and EU. Mr. Stevens later served as Asset General Manager, from April 2020 through May 2022, for the Hemophilia A program and subsequently Head of Product Strategy, from May 2022 through October 2022, overseeing program development for Spark's entire portfolio. Prior to Spark, Mr. Stevens was at GlaxoSmithKline, a global biopharma company, from January 2013 through February 2017, where he led teams focused on strategy, operations, and planning, as well as GMP clinical manufacturing operations including process transfer and cell banking. Earlier in his career he held roles of increasing responsibility at Bristol-Myers Squibb, a global biopharma company, from June 2001 through January 2013, in process engineering, manufacturing and supply chain in Massachusetts, Indiana and Puerto Rico. Mr. Stevens currently serves as President of the Board at A Haven – a non-profit family grief center in Chester County, Pennsylvania. He received his M.S. in Industrial Management from the University of Southern Indiana and a B.S. in Chemical Engineering from Purdue University.
- Sarbani Chaudhuri
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Martin Wilson
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介